Abstract
Peroxisome proliferator-activated receptorδ (PPARδ) belongs to the PPARs receptor family including PPARα, PPARδ, and PPARγ. PPARδ is a ligand-activated transcription factor that plays a critical role in regulating cancer progression. PPARδ-linked tumorigenesis was first identified in colorectal cancer, which is demonstrated by the following evidences, so PPARε is a potential drug target for colorectal cancer. In contrast, some observations show that PPARδ negatively regulates colorectal cancer event. In the present review, the recent progress of PPARδ signaling-mediated colorectal cancer is covered.
Keywords: Colorectal cancer, PPARδ, signaling.
Current Pharmaceutical Design
Title:PPARδ Signaling Regulates Colorectal Cancer
Volume: 21 Issue: 21
Author(s): Mengli You, Shuping Yuan, Juanjuan Shi and Yongzhong Hou
Affiliation:
Keywords: Colorectal cancer, PPARδ, signaling.
Abstract: Peroxisome proliferator-activated receptorδ (PPARδ) belongs to the PPARs receptor family including PPARα, PPARδ, and PPARγ. PPARδ is a ligand-activated transcription factor that plays a critical role in regulating cancer progression. PPARδ-linked tumorigenesis was first identified in colorectal cancer, which is demonstrated by the following evidences, so PPARε is a potential drug target for colorectal cancer. In contrast, some observations show that PPARδ negatively regulates colorectal cancer event. In the present review, the recent progress of PPARδ signaling-mediated colorectal cancer is covered.
Export Options
About this article
Cite this article as:
You Mengli, Yuan Shuping, Shi Juanjuan and Hou Yongzhong, PPARδ Signaling Regulates Colorectal Cancer, Current Pharmaceutical Design 2015; 21 (21) . https://dx.doi.org/10.2174/1381612821666150514104035
DOI https://dx.doi.org/10.2174/1381612821666150514104035 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Apigenin-mediated Alterations in Viability and Senescence of SW480 Colorectal Cancer Cells Persist in The Presence of L-thyroxine
Anti-Cancer Agents in Medicinal Chemistry Progress of Individualized Chemotherapy for Gastric Carcinoma Under the Guidance of Genetic Testing
Current Medicinal Chemistry Optimizing Tumor-Reactive γδT Cells for Antibody-Based Cancer Immunotherapy
Current Molecular Medicine Sam68 Promotes the Progression of Human Breast Cancer through inducing Activation of EphA3
Current Cancer Drug Targets Anti-cancer Effects of Curcumin on Head and Neck Cancers
Anti-Cancer Agents in Medicinal Chemistry Recent Progress of Small Molecular VEGFR Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry IGF-I Abuse in Sport
Current Drug Abuse Reviews Highly Efficient, Chemoselective Syntheses of 2-Methoxy-4-substituted Pyrimidines
Letters in Organic Chemistry Relationships between Serotoninergic System and Skin Fibrotic
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Protein Kinase Inhibitors in the Treatment of Pulmonary Fibrosis
Current Medicinal Chemistry All for Statins and Statins for All; An Update
Current Pharmaceutical Design Effects of Adjuvant Chelator or Chemotherapy on Dosimetry of 90Y-CC49 in Lung Cancer Patients Using 111In-CC49 as a Tracer
Drug Design Reviews - Online (Discontinued) Near Infrared Receptor-Targeted Nanoprobes for Early Diagnosis of Cancers
Current Medicinal Chemistry Drug-Loaded Nanocarriers in Tumor Targeted Drug Delivery
Current Biotechnology Natural Compounds with Proteasome Inhibitory Activity for Cancer Prevention and Treatment
Current Protein & Peptide Science Repair and Translesion DNA Polymerases as Anticancer Drug Targets
Anti-Cancer Agents in Medicinal Chemistry Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications
Current Drug Targets Targeting the Perpetrator: Breast Cancer Stem Cell Therapeutics
Current Drug Targets Interaction of Mesalasine (5-ASA) with Translational Initiation Factors eIF4 Partially Explains 5-ASA Anti-Inflammatory and Anti-Neoplastic Activities
Medicinal Chemistry Monoclonal Antibodies in the Management of Solid Tumors
Current Topics in Medicinal Chemistry